Intellia Therapeutics’ lonvoguran ziclumeran (lonvo-z) added another layer of late-stage support after the company reported new positive results tied to secondary endpoints in its Phase III HAELO trial (NCT06634420). Intellia presented and published the findings in The New England Journal of Medicine and also shared the data at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul. The therapy maintained directionally consistent efficacy, with updates including a lower monthly rate of attacks requiring on-demand treatment and a reduced rate of moderate/severe attacks during Weeks 5–28. The company also reported improvements in patient-reported AE-QoL scores by Week 28. Intellia said the data supported its rolling Biologics License Application (BLA) submission started in April and that it expects to complete the filing by year-end, targeting an FDA decision and potential launch in the first half of 2027. In parallel, the stock reaction described by STAT-linked coverage reflected investor focus on durability of response and the ability to reduce or eliminate long-term prophylaxis in treated patients.